Hemophilia A cost-effectiveness of therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
Though long-term prophylaxis has been shown to be beneficial in decreasing incidence of bleeding events, the major barrier to its implementation is high cost.  
Though long-term [[prophylaxis]] has been shown to be beneficial in decreasing incidence of bleeding events in patients with [[Hemophilia A]], the major barrier to its implementation is high cost.  


==Cost-effectiveness of therapy==
==Cost-effectiveness of therapy==

Revision as of 08:50, 27 March 2017

Hemophilia A Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hemophilia A from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hemophilia A cost-effectiveness of therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hemophilia A cost-effectiveness of therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hemophilia A cost-effectiveness of therapy

CDC on Hemophilia A cost-effectiveness of therapy

Hemophilia A cost-effectiveness of therapy in the news

Blogs on Hemophilia A cost-effectiveness of therapy

Directions to Hospitals Treating Hemophilia A

Risk calculators and risk factors for Hemophilia A cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Fahd Yunus, M.D. [2]

Overview

Though long-term prophylaxis has been shown to be beneficial in decreasing incidence of bleeding events in patients with Hemophilia A, the major barrier to its implementation is high cost.

Cost-effectiveness of therapy

Long-term prophylaxis, particularly for patients with severe hemophilia, has been shown to be cost-effective as it decreases the otherwise high cost of managing recurrent joint bleeds and improves quality of life overall. [1] Further research is required to address the issue of cost-effectiveness for therapy in hemophilia A. In particular, further research would be helpful to determine the optimal dosing schedule for prophylaxis, and the optimal target ranges of clotting factor levels. These studies are especially needed in countries with limited resources, where access to prophylaxis is limited.

References

  1. Prophylaxis: Barriers and challenges – World Federation of Hemophilia. Available at http://www.wfh.org/en/abd/prophylaxis/prophylaxis-barriers-and-challenges. Accessed on Sept 20, 2016

Template:WH Template:WS